These numbers explain why so many patients either give up on treatment or turn to compounded alternatives and discount programs
In human clinical trials, cases of thyroid cancer have been rare and occurred at similar rates in treatment and control groups
What usually happened is that the protocol stopped fitting the body it is now treating
PHILADELPHIA, July 30, 2024 /PRNewswire/ -- A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported today at the Alzheimer's Association International Conference (AAIC ) 2024, in Philadelphia and online
These potential applications are supported by small RCTs and mechanistic studies indicating ECM remodeling, antioxidant effects, and anti-inflammation [1, 2, 3, 5, 8]
What Are GLP-1s (and Why Do They Matter?) GLP-1 stands for glucagon-like peptide-1, a natural hormone that regulates appetite, blood sugar, and how quickly the stomach empties